Most people on Mounjaro lose between 15% and 21% of their body weight over about a year and a half, depending on the dose. For someone starting at 250 pounds, that translates to roughly 38 to 52 pounds. These numbers come from large clinical trials, and real-world results vary based on your starting weight, dose, diet, and activity level.
Weight Loss by Dose
Mounjaro (tirzepatide) comes in several doses, and the amount you lose scales with how high you go. In the landmark SURMOUNT-1 trial, which followed participants without diabetes for 72 weeks, the average weight loss at each dose was:
- 5 mg: 15% of body weight
- 10 mg: 19.5% of body weight
- 15 mg (maximum dose): 20.9% of body weight
People on placebo lost about 3% over the same period. At the highest dose, more than half of participants lost over 20% of their body weight, a threshold that was almost unheard of with earlier medications. About 80% of those on the 10 mg or 15 mg dose lost at least 5%.
If you have type 2 diabetes, expect somewhat lower numbers. A separate trial (SURMOUNT-2) found that people with diabetes lost 12.8% on the 10 mg dose and 14.7% on the 15 mg dose over 72 weeks. Diabetes makes weight loss harder because of how the condition affects metabolism and insulin levels, but those results are still significant.
What the Timeline Looks Like
Everyone starts at 2.5 mg once weekly. This is purely a starter dose to let your body adjust, not the dose that drives major weight loss. After four weeks, you move up to 5 mg. From there, your doctor can increase by 2.5 mg every four weeks or longer until you reach a dose that works, up to a maximum of 15 mg.
Most people notice some weight loss within the first two to four weeks, typically 2 to 4 pounds as appetite suppression kicks in and portion sizes shrink naturally. Once you reach the 5 mg dose in months two and three, weight loss tends to accelerate to about 1 to 2 pounds per week. The steepest losses generally happen between months three and nine as you titrate to higher doses. By the end of a full 72-week course, the curve flattens, meaning you’re mostly maintaining what you’ve lost rather than continuing to drop rapidly.
How Mounjaro Compares to Ozempic
A head-to-head trial published in 2025 put the question to rest directly. Over 72 weeks, people on tirzepatide (the active ingredient in Mounjaro) lost about 50 pounds, or 20.2% of their body weight. Those on semaglutide (the ingredient in Ozempic and Wegovy) lost about 33 pounds, or 13.7%. That’s roughly 50% more weight loss with tirzepatide.
The difference comes down to how the drugs work. Semaglutide activates one gut hormone pathway that reduces appetite and slows digestion. Tirzepatide activates two: the same one semaglutide targets, plus a second pathway involved in energy balance and fat storage. This dual action appears to produce stronger appetite suppression and more efficient calorie use.
Why Individual Results Vary
Clinical trial averages don’t tell the whole story. Some people lose 25% or more of their body weight, while others lose closer to 10%. Several factors influence where you fall. Your starting weight matters: people with more to lose often see larger absolute losses early on. Whether you have diabetes plays a role, as noted above. How well you tolerate higher doses is also key, since some people stay at 10 mg due to side effects (mostly nausea) rather than reaching 15 mg.
Diet and exercise aren’t optional extras. Trial participants were all counseled to eat fewer calories and move more. The drug reduces your appetite dramatically, which makes eating less feel far more manageable than willpower alone, but it works best when paired with deliberate changes to what and how much you eat.
What Happens If You Stop
This is the part most people don’t want to hear, but it’s important. Data from the SURMOUNT-4 trial tracked people who had already lost at least 10% of their weight on tirzepatide and then either continued the medication or switched to placebo. Among those who stopped, 82% regained more than 25% of the weight they had lost within one year. A quarter of them regained 75% or more of their lost weight.
This doesn’t mean the medication “doesn’t work.” It means obesity is a chronic condition, and tirzepatide treats it the way blood pressure medication treats hypertension. The effect lasts as long as the treatment does. If you and your doctor decide to stop, a gradual taper combined with strong diet and exercise habits gives you the best chance of holding onto some of the loss, but significant regain is the norm rather than the exception.
A Quick Note on Branding
Mounjaro is technically FDA-approved for type 2 diabetes. The same drug, tirzepatide, is sold under the name Zepbound when prescribed specifically for weight management in people with obesity or overweight with at least one related health condition. The weight loss data applies to both since the active ingredient is identical. Your insurance coverage and out-of-pocket cost may differ depending on which brand is prescribed and why.